CSTL Q2 2024 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$805M

Q2 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$87M+73.5% YoY

Gross Profit

$72M83.3% margin

Operating Income

$5M5.8% margin

Net Income

$9M10.3% margin

EPS (Diluted)

$0.31

QoQ Revenue Growth

+19.2%

Cash Flow

Operating Cash Flow

$24M

Free Cash Flow

$19M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$487M

Total Liabilities

$63M

Stockholders' Equity

$424M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$87M	$50M	+73.5%
Gross Profit	$72M	$39M	+85.5%
Operating Income	$5M	-$21M	+123.7%
Net Income	$9M	-$19M	+147.5%

Revenue Segments

Dermatologic

$69M100%